Drugs / Etvax
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05178134 Comparator | Nov 2021 → Oct 2022 | — | Scandinavian Biopharma AB | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ETVAX | “A Phase 2 Immunological Bridging Study Assessing the Non-inferiority of a New Formulation of ETVAX®.” NCT05178134 ↗ |
| Route | Oral | “Eligible subjects will be randomized on Day 1 (Visit 2) to receive either of the two oral formulations of ETVAX” NCT05178134 ↗ |